Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction

Young Hoon Jeong, Seung Whan Lee, Whan Lee Cheol, Myeong Ki Hong, Jae Joong Kim, Seong Wook Park, Seung Jung Park, Duk Woo Park, Young Hak Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Several cardiac biomarkers have been shown to have predictive values for the development of cardiovascular disease and clinical outcome after events, and are now broadly used by clinicians. Little is known about the utility of these biomarker values on admission in ST-elevation myocardial infarction (STEMI) cases of primary drug-eluting stent (DES) implantation and intense medical therapy. Hypothesis: Because little is known about the utility of these biomarkers on admission in ST-elevation myocardial infarction (STEMI) in cases primary drug-eluting stent (DES) implantation and intense medical therapy, we evaluated clinical outcomes. Methods: We enrolled 207 consecutive STEMI patients treated with primary stenting (mean age, 57.3±12.0 y). We evaluated the association between B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP) on admission, and death, reinfarction, and new or worsening congestive heart failure (CHF) through 1 y. Results: In backward-elimination models including all biomarkers, only the cTnI level was retained as a predictor of 1-y CHF (odds ratio [OR]: 1.017, 95% confidence interval [CI]: 1.001-1.034, p=0.039). There were no predictors in terms of 1-y death, reinfarction, and composite endpoint. When we applied a simple score system, in which patients were categorized on the basis of the number of elevated biomarkers, the 1-y risks of death (p=0.600), reinfarction (p=0.185), and composite endpoint (p=0.620) did not increase in proportion to the number of elevated biomarkers on admission. One-y CHF only tended to increase according to the number of elevated biomarkers (p=0.067). Conclusions: The use of cardiac biomarkers on admission, in each or in combination, had only a minimal impact for the prediction of long-term cardiovascular events after primary stenting in STEMI patients.

Original languageEnglish
Pages (from-to)572-579
Number of pages8
JournalClinical Cardiology
Volume31
Issue number12
DOIs
Publication statusPublished - 2008 Dec 1

Fingerprint

Biomarkers
Troponin I
Drug-Eluting Stents
Heart Failure
ST Elevation Myocardial Infarction
Brain Natriuretic Peptide
C-Reactive Protein
Cardiovascular Diseases
Odds Ratio
Confidence Intervals
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Jeong, Young Hoon ; Lee, Seung Whan ; Cheol, Whan Lee ; Hong, Myeong Ki ; Kim, Jae Joong ; Park, Seong Wook ; Park, Seung Jung ; Park, Duk Woo ; Kim, Young Hak. / Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. In: Clinical Cardiology. 2008 ; Vol. 31, No. 12. pp. 572-579.
@article{dbda960bcd814711a0d439bce782e053,
title = "Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction",
abstract = "Background: Several cardiac biomarkers have been shown to have predictive values for the development of cardiovascular disease and clinical outcome after events, and are now broadly used by clinicians. Little is known about the utility of these biomarker values on admission in ST-elevation myocardial infarction (STEMI) cases of primary drug-eluting stent (DES) implantation and intense medical therapy. Hypothesis: Because little is known about the utility of these biomarkers on admission in ST-elevation myocardial infarction (STEMI) in cases primary drug-eluting stent (DES) implantation and intense medical therapy, we evaluated clinical outcomes. Methods: We enrolled 207 consecutive STEMI patients treated with primary stenting (mean age, 57.3±12.0 y). We evaluated the association between B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP) on admission, and death, reinfarction, and new or worsening congestive heart failure (CHF) through 1 y. Results: In backward-elimination models including all biomarkers, only the cTnI level was retained as a predictor of 1-y CHF (odds ratio [OR]: 1.017, 95{\%} confidence interval [CI]: 1.001-1.034, p=0.039). There were no predictors in terms of 1-y death, reinfarction, and composite endpoint. When we applied a simple score system, in which patients were categorized on the basis of the number of elevated biomarkers, the 1-y risks of death (p=0.600), reinfarction (p=0.185), and composite endpoint (p=0.620) did not increase in proportion to the number of elevated biomarkers on admission. One-y CHF only tended to increase according to the number of elevated biomarkers (p=0.067). Conclusions: The use of cardiac biomarkers on admission, in each or in combination, had only a minimal impact for the prediction of long-term cardiovascular events after primary stenting in STEMI patients.",
author = "Jeong, {Young Hoon} and Lee, {Seung Whan} and Cheol, {Whan Lee} and Hong, {Myeong Ki} and Kim, {Jae Joong} and Park, {Seong Wook} and Park, {Seung Jung} and Park, {Duk Woo} and Kim, {Young Hak}",
year = "2008",
month = "12",
day = "1",
doi = "10.1002/clc.20403",
language = "English",
volume = "31",
pages = "572--579",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. / Jeong, Young Hoon; Lee, Seung Whan; Cheol, Whan Lee; Hong, Myeong Ki; Kim, Jae Joong; Park, Seong Wook; Park, Seung Jung; Park, Duk Woo; Kim, Young Hak.

In: Clinical Cardiology, Vol. 31, No. 12, 01.12.2008, p. 572-579.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction

AU - Jeong, Young Hoon

AU - Lee, Seung Whan

AU - Cheol, Whan Lee

AU - Hong, Myeong Ki

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Park, Seung Jung

AU - Park, Duk Woo

AU - Kim, Young Hak

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background: Several cardiac biomarkers have been shown to have predictive values for the development of cardiovascular disease and clinical outcome after events, and are now broadly used by clinicians. Little is known about the utility of these biomarker values on admission in ST-elevation myocardial infarction (STEMI) cases of primary drug-eluting stent (DES) implantation and intense medical therapy. Hypothesis: Because little is known about the utility of these biomarkers on admission in ST-elevation myocardial infarction (STEMI) in cases primary drug-eluting stent (DES) implantation and intense medical therapy, we evaluated clinical outcomes. Methods: We enrolled 207 consecutive STEMI patients treated with primary stenting (mean age, 57.3±12.0 y). We evaluated the association between B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP) on admission, and death, reinfarction, and new or worsening congestive heart failure (CHF) through 1 y. Results: In backward-elimination models including all biomarkers, only the cTnI level was retained as a predictor of 1-y CHF (odds ratio [OR]: 1.017, 95% confidence interval [CI]: 1.001-1.034, p=0.039). There were no predictors in terms of 1-y death, reinfarction, and composite endpoint. When we applied a simple score system, in which patients were categorized on the basis of the number of elevated biomarkers, the 1-y risks of death (p=0.600), reinfarction (p=0.185), and composite endpoint (p=0.620) did not increase in proportion to the number of elevated biomarkers on admission. One-y CHF only tended to increase according to the number of elevated biomarkers (p=0.067). Conclusions: The use of cardiac biomarkers on admission, in each or in combination, had only a minimal impact for the prediction of long-term cardiovascular events after primary stenting in STEMI patients.

AB - Background: Several cardiac biomarkers have been shown to have predictive values for the development of cardiovascular disease and clinical outcome after events, and are now broadly used by clinicians. Little is known about the utility of these biomarker values on admission in ST-elevation myocardial infarction (STEMI) cases of primary drug-eluting stent (DES) implantation and intense medical therapy. Hypothesis: Because little is known about the utility of these biomarkers on admission in ST-elevation myocardial infarction (STEMI) in cases primary drug-eluting stent (DES) implantation and intense medical therapy, we evaluated clinical outcomes. Methods: We enrolled 207 consecutive STEMI patients treated with primary stenting (mean age, 57.3±12.0 y). We evaluated the association between B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP) on admission, and death, reinfarction, and new or worsening congestive heart failure (CHF) through 1 y. Results: In backward-elimination models including all biomarkers, only the cTnI level was retained as a predictor of 1-y CHF (odds ratio [OR]: 1.017, 95% confidence interval [CI]: 1.001-1.034, p=0.039). There were no predictors in terms of 1-y death, reinfarction, and composite endpoint. When we applied a simple score system, in which patients were categorized on the basis of the number of elevated biomarkers, the 1-y risks of death (p=0.600), reinfarction (p=0.185), and composite endpoint (p=0.620) did not increase in proportion to the number of elevated biomarkers on admission. One-y CHF only tended to increase according to the number of elevated biomarkers (p=0.067). Conclusions: The use of cardiac biomarkers on admission, in each or in combination, had only a minimal impact for the prediction of long-term cardiovascular events after primary stenting in STEMI patients.

UR - http://www.scopus.com/inward/record.url?scp=58149083996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149083996&partnerID=8YFLogxK

U2 - 10.1002/clc.20403

DO - 10.1002/clc.20403

M3 - Article

C2 - 19072878

AN - SCOPUS:58149083996

VL - 31

SP - 572

EP - 579

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 12

ER -